Table 1.
Clinical, Laboratory, Radiologic, and Treatment Characteristics of the Prospective Cohort (n = 80).
| Characteristics | Data |
|---|---|
| Age, median (IQR) | 61 (53 – 68) |
| Female, n (%) | 23 (28.8) |
| Diagnosis, n (%) | |
| HCC | 61 (76) |
| Healthy | 8 (10) |
| Cirrhosis | 7 (9) |
| Adenoma | 4 (5) |
| Laboratory | |
| Physiologic MELD, median (IQR) | 8 (7 – 13) |
| Childs Class, n (%) | |
| A | 60 (75) |
| B | 9 (11.5) |
| C | 11 (13.8) |
| Most recent AFP, median (IQR) | 24 (5 – 790) |
| Maximum pre-draw AFP, median (IQR) | 38 (7 – 1148) |
| HCC Cause, n (%) | |
| HCV | 40 (65.6) |
| HBV | 11 (18) |
| NASH | 5 (8.2) |
| Other | 3 (4.9) |
| Unknown/non-cirrhotic | 2 (3.3) |
| Radiologic | |
| Maximum tumor diameter, median (IQR) | 4.6 (3.4 – 6.7) |
| Cumulative tumor diameter, median (IQR) | 6.2 (3.5 – 9.7) |
| Predraw treatment characteristics | |
| Any predraw treatment, n (% of all HCC) | 25 (41.0) |
| Early stage (within UCSF) | 8 (32.0) |
| Advanced stage (outside UCSF) | 17 (68.0) |
| No. of predraw treatments, n (% of treated pts) | |
| 1 | 12 (48) |
| 2 | 2 (8) |
| 3 | 5 (20) |
| 4+ | 6 (24) |
| Type of treatment, n (% of treated pts) | |
| Sorafenib | 10 (40) |
| Nivolumab | 4 (16) |
| Other systemic therapy | 1 (4) |
| Radioembolization (Y90) | 2 (8) |
| Transarterial chemoembolization (TACE) | 12 (48) |
| Thermal ablation | 9 (36) |
| Transplant criteria | |
| Within Milan criteria, n (%) | 23 (37.7) |
| Outside Milan, within UCSF criteria, n (%) | 8 (13.1) |
| Outside UCSF criteria/locoregional only, n (%) | 21 (34.4) |
| Metastatic disease, n (%) | 9 (14.8) |
| BCLC stage | |
| A | 11 (18) |
| B | 17 (27.9) |
| C | 26 (42.6) |
| D | 7 (11.5) |
IQR – interquartile range, HCC – hepatocellular carcinoma, MELD – Model for End-Stage Liver Disease, AFP – alphafetoprotein, HCV – hepatitis C virus, HBV – hepatitis B virus, NASH – Nonalcholic steatohepatitis, BCLC – Barcelona clinic liver cancer stage